FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029422059> ?p ?o ?g. }

• W2029422059 endingPage "962" @default.
• W2029422059 startingPage "959" @default.
• W2029422059 abstract "No AccessJournal of UrologyINVESTIGATIVE UROLOGY1 Mar 2001TUMOR ASSOCIATED TRYPSIN INHIBITOR AS A PROGNOSTIC FACTOR IN RENAL CELL CARCINOMA ANNUKKA PAJU, JAN JACOBSEN, TORGNY RASMUSON, ULF-HÅKAN STENMAN, and BÖRJE LJUNGBERG ANNUKKA PAJUANNUKKA PAJU More articles by this author , JAN JACOBSENJAN JACOBSEN More articles by this author , TORGNY RASMUSONTORGNY RASMUSON More articles by this author , ULF-HÅKAN STENMANULF-HÅKAN STENMAN More articles by this author , and BÖRJE LJUNGBERGBÖRJE LJUNGBERG More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)66584-6AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We analyzed the prognostic significance of pretreatment serum tumor associated trypsin inhibitor in renal cell carcinoma. Materials and Methods: Serum samples were obtained before surgery from 188 patients who underwent radical nephrectomy for renal cell carcinoma. Median followup of living patients was 8.5 years. Serum tumor associated trypsin inhibitor was measured by a time resolved immunofluorometric assay. Statistical analysis was performed using the Kaplan-Meier method, log rank and stratified log rank tests. Results: Preoperatively serum tumor associated trypsin inhibitor was elevated with a cutoff 16 μg./l. in 48% of the patients with normal serum creatinine. The concentration in patients with cancer was significantly higher than in controls (p <0.0001). The serum level correlated with clinical stage and nuclear grade. Patients with an elevated level had significantly shorter survival time than those with a normal level (p = 0.005). Stratified log rank test demonstrated that tumor associated trypsin inhibitor was a prognostic factor independent of stage and grade in all patients as well as in those with nonmetastatic disease. Conclusions: Increased preoperative serum tumor associated trypsin inhibitor was associated with poor survival in renal cell carcinoma. The serum level was an independent prognostic variable. Preoperative serum tumor associated trypsin inhibitor appears to be a useful predictive factor that may be used to identify patients at increased risk of aggressive disease. References 1 : The Heidelberg classification of renal cell tumours. J Pathol1997; 183: 131. Google Scholar 2 : Renal cell carcinoma. Current prognostic factors. Cancer1997; 80: 981. Google Scholar 3 : Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol1982; 6: 655. Google Scholar 4 : Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases. Cancer1988; 61: 1639. Google Scholar 5 : Renal carcinoma. Reevaluation of prognostic factors. Cancer1988; 61: 1192. Google Scholar 6 : Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma. Cancer1997; 80: 1768. Google Scholar 7 : Clinical significance of tumor angiogenesis in patients with localized renal cell carcinoma. Urology1998; 51: 693. Google Scholar 8 : Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br J Cancer1999; 79: 1182. Google Scholar 9 : Neuroendocrine differentiation in renal cell carcinoma. Evaluation of chromogranin A and neuron-specific enolase. Acta Oncol1999; 38: 623. Google Scholar 10 : Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?. Clin Cancer Res1997; 3: 2451. Google Scholar 11 : Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem1982; 257: 13713. Google Scholar 12 : Biology and function of tumor-associated trypsin inhibitor. Scand J Clin Lab Invest1991; 51: 5. Google Scholar 13 : Tumour-associated trypsin inhibitor (TATI) in ovarian cancer. Br J Cancer1988; 57: 304. Google Scholar 14 : Pre-operative serum level of tumour-associated trypsin inhibitor and residual tumour size as prognostic indicators in stage III epithelial ovarian cancer. Br J Obstet Gynaecol1998; 105: 508. Google Scholar 15 : Tumour-associated trypsin inhibitor and renal cell carcinoma. Eur Urol1995; 27: 223. Google Scholar 16 : Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients. Int J Cancer1999; 83: 486. Google Scholar 17 : TNM Classification of Malignant Tumors. New York, Wiley-Liss: International Union Against Cancer1997: 180. Google Scholar 18 : Diagnosis and management of renal cell carcinoma. A clinical and pathological study of 309 cases. Cancer1971; 28: 1165. Google Scholar 19 : Heterogeneity in renal cell carcinoma and its impact on prognosis: a flow cystometric study. Br J Cancer1996; 74: 123. Google Scholar 20 : Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. J Immunol Methods1993; 161: 97. Google Scholar 21 : Serum tumour-associated trypsin inhibitor (TATI) and renal function. Scand J Clin Lab Invest1996; 56: 653. Google Scholar 22 : Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix. Cancer Res1991; 51: 2107. Google Scholar 23 : Activation of type IV procollagenases by human tumor-associated trypsin-2. J Biol Chem1997; 272: 21067. Google Scholar 24 : Expression of trypsin by epithelial cells of various tissues, leukocytes, and neurons in human and mouse. Am J Pathol1998; 153: 937. Google Scholar From the Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland, and Departments of Urology and Andrology and Oncology, Umeå University, Umeå, Sweden© 2001 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 165Issue 3March 2001Page: 959-962 Advertisement Copyright & Permissions© 2001 by American Urological Association, Inc.Keywordstrypsin inhibitorskidneyprognosiscarcinoma, renal cellMetricsAuthor Information ANNUKKA PAJU More articles by this author JAN JACOBSEN More articles by this author TORGNY RASMUSON More articles by this author ULF-HÅKAN STENMAN More articles by this author BÖRJE LJUNGBERG More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2029422059 created "2016-06-24" @default.
• W2029422059 creator A5029542738 @default.
• W2029422059 creator A5051002496 @default.
• W2029422059 creator A5054008947 @default.
• W2029422059 creator A5062214950 @default.
• W2029422059 creator A5067500831 @default.
• W2029422059 date "2001-03-01" @default.
• W2029422059 modified "2023-10-16" @default.
• W2029422059 title "TUMOR ASSOCIATED TRYPSIN INHIBITOR AS A PROGNOSTIC FACTOR IN RENAL CELL CARCINOMA" @default.
• W2029422059 cites W1522731119 @default.
• W2029422059 cites W1964312188 @default.
• W2029422059 cites W1994688213 @default.
• W2029422059 cites W2003516005 @default.
• W2029422059 cites W2007691725 @default.
• W2029422059 cites W2008100726 @default.
• W2029422059 cites W2022322062 @default.
• W2029422059 cites W2024022674 @default.
• W2029422059 cites W2038592376 @default.
• W2029422059 cites W2039545078 @default.
• W2029422059 cites W2045112409 @default.
• W2029422059 cites W2057377251 @default.
• W2029422059 cites W2080723400 @default.
• W2029422059 cites W2086548792 @default.
• W2029422059 cites W2101844493 @default.
• W2029422059 cites W2112775523 @default.
• W2029422059 cites W2147971993 @default.
• W2029422059 cites W2152704813 @default.
• W2029422059 cites W2160896252 @default.
• W2029422059 cites W2410157744 @default.
• W2029422059 cites W4206236151 @default.
• W2029422059 doi "https://doi.org/10.1016/s0022-5347(05)66584-6" @default.
• W2029422059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11176522" @default.
• W2029422059 hasPublicationYear "2001" @default.
• W2029422059 type Work @default.
• W2029422059 sameAs 2029422059 @default.
• W2029422059 citedByCount "33" @default.
• W2029422059 countsByYear W20294220592012 @default.
• W2029422059 countsByYear W20294220592013 @default.
• W2029422059 countsByYear W20294220592014 @default.
• W2029422059 countsByYear W20294220592015 @default.
• W2029422059 countsByYear W20294220592016 @default.
• W2029422059 countsByYear W20294220592017 @default.
• W2029422059 countsByYear W20294220592018 @default.
• W2029422059 countsByYear W20294220592019 @default.
• W2029422059 countsByYear W20294220592020 @default.
• W2029422059 crossrefType "journal-article" @default.
• W2029422059 hasAuthorship W2029422059A5029542738 @default.
• W2029422059 hasAuthorship W2029422059A5051002496 @default.
• W2029422059 hasAuthorship W2029422059A5054008947 @default.
• W2029422059 hasAuthorship W2029422059A5062214950 @default.
• W2029422059 hasAuthorship W2029422059A5067500831 @default.
• W2029422059 hasConcept C10515644 @default.
• W2029422059 hasConcept C121608353 @default.
• W2029422059 hasConcept C126322002 @default.
• W2029422059 hasConcept C126894567 @default.
• W2029422059 hasConcept C143998085 @default.
• W2029422059 hasConcept C159641895 @default.
• W2029422059 hasConcept C181199279 @default.
• W2029422059 hasConcept C185592680 @default.
• W2029422059 hasConcept C2776351012 @default.
• W2029422059 hasConcept C2777472916 @default.
• W2029422059 hasConcept C2777546739 @default.
• W2029422059 hasConcept C2780091579 @default.
• W2029422059 hasConcept C2780227381 @default.
• W2029422059 hasConcept C2780306776 @default.
• W2029422059 hasConcept C2780340462 @default.
• W2029422059 hasConcept C55493867 @default.
• W2029422059 hasConcept C66339696 @default.
• W2029422059 hasConcept C71924100 @default.
• W2029422059 hasConcept C90924648 @default.
• W2029422059 hasConceptScore W2029422059C10515644 @default.
• W2029422059 hasConceptScore W2029422059C121608353 @default.
• W2029422059 hasConceptScore W2029422059C126322002 @default.
• W2029422059 hasConceptScore W2029422059C126894567 @default.
• W2029422059 hasConceptScore W2029422059C143998085 @default.
• W2029422059 hasConceptScore W2029422059C159641895 @default.
• W2029422059 hasConceptScore W2029422059C181199279 @default.
• W2029422059 hasConceptScore W2029422059C185592680 @default.
• W2029422059 hasConceptScore W2029422059C2776351012 @default.
• W2029422059 hasConceptScore W2029422059C2777472916 @default.
• W2029422059 hasConceptScore W2029422059C2777546739 @default.
• W2029422059 hasConceptScore W2029422059C2780091579 @default.
• W2029422059 hasConceptScore W2029422059C2780227381 @default.
• W2029422059 hasConceptScore W2029422059C2780306776 @default.
• W2029422059 hasConceptScore W2029422059C2780340462 @default.
• W2029422059 hasConceptScore W2029422059C55493867 @default.
• W2029422059 hasConceptScore W2029422059C66339696 @default.
• W2029422059 hasConceptScore W2029422059C71924100 @default.
• W2029422059 hasConceptScore W2029422059C90924648 @default.
• W2029422059 hasIssue "3" @default.
• W2029422059 hasLocation W20294220591 @default.
• W2029422059 hasLocation W20294220592 @default.
• W2029422059 hasOpenAccess W2029422059 @default.
• W2029422059 hasPrimaryLocation W20294220591 @default.
• W2029422059 hasRelatedWork W1600584716 @default.
• W2029422059 hasRelatedWork W2007991740 @default.
• W2029422059 hasRelatedWork W2011497873 @default.

• next